

## REFERENCES

- Abetimus (2003)*: Abetimus sodium, LJP 394 . BioDrugs 17: 212–215.
- ACR The American College of Rheumatology (1999)*: Nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum.* **42** (4): 599–608.
- Adnan N. Kiani, Kristen Johnson, Catherine Chen, Edward Diehl, Huaizhong HU, Ganesh Vasudevan, Sukhminder Singh, Laurence S. Magder, Stuart J. Knechtle and Michelle Petri (2009)*: Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. *The Journal of Rheumatology* ; vol. 36 no. 10 2224-2230.
- Alexopoulos E., Cameron J.S. and Hartley B.H. (1999)*: Correlation of interstitial cells with glomerular function. *Kidney Int.*, 37 : 100 – 109.
- Allison A.C. and Eugui E.M. (2000)*: Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology* 47: 85–118.
- Amander T. Clark and John F. Bertram(1999)*: Molecular regulation of nephron endowment. *Am J Physiol Renal Physiol* **276**: Vol. 276, Issue 4, F485-F497.
- Amoura Z., Koutouzov S. and Chabre H. (2000)*: Presence of anti – nucleosome autoantibodies in a restricted set of c onnective tissue diseases. Anti – nucleosome autoantibodies of the IgG3 subclass are marker of renal pathogenicity in systemic lupus erythematosus. *Arthritis rheum*, 43 : 76– 84.
- Andrade F., Casciola-Rosen L. and Rosen A.(2000)*: Apoptosis in systemic lupus erythematosus. Clinical implications. *Rheum Dis Clin North Am.* May; 26 (2) : 215-27.
- Anisur Rahman and David A. Isenberg (February 28, 2008)*. "Review Article: systemic Lupus Erythematosus". *N Engl J Med* **358** (9): 929–939.

- Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. (2009):** Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol* ;20(5):1103-12.
- Alzawawy A. , Zohary M., Ablordiny M. and Eldalie M. (2009):** Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. *International Journal of Rheumatic Diseases* Volume 12, Issue 4, P: 311-318.
- Austin H.A., Muenz, L.R. and Joyce K.M. (1984):** Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. *Kidney Int.*, 25: 689-695.
- Baggiolini M. (1998):** Chemokines and leukocyte traffic. *Nature*, 392, 65 – 568.
- Baggiolini M. (2001):** Chemokines in pathology and medicine. *Journal of Internal Medicine*, 250 : 91-104.
- Baggiolini M., Dehald B. and Moser B. (1994):** IL8 and related chemotactic cytokines CXC and CC Cheokines. *Adv Immunol.*, 55 : 97 – 179.
- Baggiolini M., Dewald B. and Moser B. (1997):** Human chemokines : an update *An Rev. Immunol.*, 15 : 675 – 705.
- Balow J.E., Austin H.A. 3<sup>rd</sup> (2003):** Therapy of membranous nephropathy in systemic lupus erythematosus. *Semin Nephrol* 23: 386–391.
- Bana B., Luckow B., Maller M., Halthofer H., Nelson P.J., Schadde E., Brigl M., Halvey D., Reinhart B. and Schlondorff D. (1999):** Chemokine and chemokine receptor expression in a novel human mesangial cell line. *J. Am. Soc. Nephrol.*, 10 : 2314 – 2322.
- Bansal V.K. and Beto J.A. (1997):** Treatment of lupus nephritis: A meta-analysis of clinical trials. *Am J Kidney Dis* 29: 193–199.
- Barres P.J. (1997):** Nuclear factor kappa B. In. *J. biochem. Cell Biol.*, 29

: 867 – 870.

**Baumann I., Kolowos W., Voll R.E., Manger B., Gaipf U., Neuhuber W.L., Kirchner T., Kalden J.R. and Herrmann M. (2002):** Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. *Arthritis Rheum* 46: 191–201.

**Bazan J.F., Bacon K.B., Hardiman G, Wang W., Soo K., Rossi D. and Zlotnik A. (1997):** A new class of membrane – bound chemokine with a CX3C motif. *Nature*, 385 : 640.

**Beck L.H., David J. and Salant D.J.(2009) :** Treatment of membranous lupus nephritis: where are we now?. *J Am Soc Nephrol* ; 20:690

**Belmont H.M., Storch M., Buyon J. and Abramson S. (1998):** New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. *Lupus* 4:104-108.

**Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J. and Pascual V. (2003):** Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J Exp Med* 197: 711–723.

**Berden J.H., Grootsholten C., Jurgen W.C., Van der Vlag J. (2002):** Lupus nephritis: A nucleosome waste disposal defect? *J Nephrol* 15 [Suppl 6]: S1–S10.

**Bernardo A. Mello and Yuhai Tu (2007).** "Effects of Adaptation in Maintaining High Sensitivity over a Wide Range of Backgrounds for *Escherichia coli* Chemotaxis". *Biophysical Journal* 92 (7): 2329–2337.

**Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., Mitchell D.A., Cook H.T., Butler P.J., Walport M.J. and Pepys M.B. (1999):** Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. *Nat Med* 5: 694–697.

- Bischoff S.C., Krieger M., Brunner T. and Dahinden C.A. (1992):** MCP-1 is a potent activator of human basophils. *J. Exp. Med.*, 125 ; 1271.
- Bombardier, C.; Gladman, D.D.; Urowitz, M.B. and Caron D. (1992):** Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum.*, 35:630–640.
- Boumpas D.T., Austin III H.A., Vaughn E.M., Klippel J.H., Steinberg A.D., Yarboro C.H. and Balow J.E. (1992):** Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. *Lancet* 340:741-745.
- Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., Vaishnav A.: BG9588 Lupus Nephritis Trial Group (2003):** A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. *Arthritis Rheum* 48: 719–727.
- Brad H., Rovin M.D., Nathaniel Doe M.D. and Laura C. (1996):** Monocyte chemoattractant protein-1 in patients with glomerular diseases. *American Journal of Kidney disease*, 27 (5) : 640 – 46.
- Brams P, Black A, Padlan E.A., et al. (2001):** A humanized anti-human CD 154 monoclonal antibody blocks CD154-CD 40 mediated human B cell activation.; 1 (2): 277-94.
- Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth C.L., et al. (2002):** Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. *Neurology*; 58:1214–20.
- Briggs J.D. and Jones E. (1999):** Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. *Nephrol Dial Transplant* 14: 570–575.

- Bruns A., Blass S., Hausdorf G., Burmester G.R. and Hiepe F. (2000):** Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. *Arthritis Rheum* 43: 2307–2315.
- Bujan S., Ordi- Ros J., Paredes J., Mauri M., Matas L., Cortes J. and Vilardell M. (2003):** Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. *Ann Rheum Dis*; 62 (9):859- 865.
- Butcher E.C. and Picker L.J. (1996):** Lymphocyte homing and homeostasis. *Science*, 272 : 60.
- Buyon J.P. (2001):** Clinical and laboratory features of systemic lupus erythematosus. In : *Primer on the rheumatic diseases*. 12<sup>th</sup> ed., Edited by : Klippel JH. Published by Arthritis Foundation. 1330 West Peachtree Atlanta Georgia. 30309. Chapter 17 : 335 – 346.
- Cabral A.R. and Alarcon – Segovia D. (1997):** Autoantibodies in systemic lupus erythematosus (review). *Curr Opin rheumatol.*, 9 : 387.
- Cameron J.S. (1999):** Lupus nephritis. *J Am Soc Nephrol* 10: 413–424.
- Carneiro E., Reis C., Pinto P., et al. (2006):** Systemic lupus erythematosus: imaging of central nervous system involvement by magnetic resonance. *Acta Med Port.*; 19(6):459-65. Epub May 14.
- Casciola-Rosen L.A., Anhalt G. and Rosen A. (1994):** Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. *J Exp Med* 179: 1083–1086.
- Chan R.W., Lai F.M., Li E.K., Tam L.S., Wong T.Y., Szeto C.Y., et al. (2004)** Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. *Arthritis Rheum* ;50:2882e90.
- Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., Lau C.S., Wong A.K., Tong M.K., Chan K.W. and Lai K.N. (2000):** Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. *Hong Kong-Guangzhou*

- Nephrology Study Group. *N. Engl. J. Med.* 343: 1156–1162.
- Charles D., Jermy B., Tammy D., et al. (2000):** Urinary monocyte chemoattractant pritein-1 (MCP-1) is a marker of active renal vasculitis. European Renal Association- European Dialysis and Transplant Assoc. *Oxford Journal* **19** (11), 2761–8.
- Charo I.F. (1999):** CCR2 : From cloning to the creation of knockout mice. *Chem. Immunol.*, 72 : 20 – 41.
- Charo I.F., Myers S.J. and Herman A.(1994):** Molecular cloning and functional expression of two monocyte chemoattractant protein -1 receptors reveals alternative splicing of the carboxyl-terminal tails. *Proc. Natl. Acad Sci. USA*, 91 : 2752 – 2756.
- Christie M. And Bartels (2009):** Systemic Lupus Erythematosus. eMedicine Specialties > Rheumatology > Systemic Rheumatic diseases.
- Chunsun D.A.I., Zhihong L.I.U., Hong Z.H.O.U. and Leishi L.I. (2001):** Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. *Chinese Medical Journal*, 2001, Vol. 114 No. 8.
- Churg, J.; Bernstein, J. and Glassock, R. J. (1995):** Lupus nephritis. In *Renal Diseases. Classification and atlas of glomerular diseases.* Second ed. New York, Igaku-Shoin, p. 151.
- Clynes R., Dumitru C. & Ravetch J.V. (1998):** Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science*; 279: 1052–1054.
- Cockwell P., Howie A.J., Adu D. and Savage C.O. (1998):** In situ analysis of c-C chemokine mRNA in human gloermulonephritis. *Kidney Int*, 54 : 827 – 836.
- Contreras G, Pardo V, Leclercq B., Lenz O., Tozman E., O Nan P. and Roth D. (2004):** Sequential therapies for proliferative lupus nephritis. *N Engl J Med* 350: 971–980.

- Costenbader K.H., Feskanich D., Stampfer M.J. and Karlson E.W. (2007):** Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. *Arthritis Rheum.* 56(4):1251-62.
- Datta S.K. and Kaliyaperumal A. (1997):** Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. *Ann N Y Acad Sci* 815: 155–170.
- Daugas E., NOCHY D & HUONG DULT et al.** Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. *J AM Soc Nephrol* , 13:42-52.
- D'Cruz D.P., Khamashta M.A. and Hughes G.R. (2007).** "Systemic lupus erythematosus". *Lancet* 369 (9561): 587–96.
- Dong Qing Ye, Yi Song Hu, Xiang Pei Li, Shi Gui Yang, Jia Hu Hao, Fen Huang and Xue Jun Zhang. (2005):** The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. *Arch Dermatol.* 296.
- Dooley M.A. (2007):** Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus*. 7<sup>th</sup> ed. Philadelphia, PA: Lippincott Williams & Wilkins :1112-30.
- Dooley M.A., Hogan S., Jennette C. and Falk R. (1997):** Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. *Kidney Int* 51: 1188–1195.
- Du L.T.H., Piette J.C., Faucher C., Wechsler B., Bletry O., Beaufils H., Baumelou A. and Godeau P. (1991):** Efficacy and limits of intravenous cyclophosphamide (IVCP) in systemic lupus erythematosus (SLE). An open study in 45 cases. *Arth Rheum* 34:S58.

- Eddy A.A. (1996):** Molecular insights in to renal interstitial fibrosis. *J. Am. Soc Nephrol.*, 7 : 2495 – 2508.
- Edworthy S.M. (2001):** Clinical manifestations of systemic lupus erythematosus. In ; "Kelley's Textbook of Rheumatology" 6<sup>th</sup> ed., Ruddy S., Harris ED, Sledge CB (ed). W.B. Saunder Co, Philadelphia. Chapter 74 : 1105 – 1124.
- Edworthy S.M.(2005):** Clinical Manifestations of Systemic Lupus Erythematosus. In: Harris ED, et al, eds. *Kelley's Textbook of Rheumatology*. 7<sup>th</sup> ed. Saunders; 1201-24.
- Edworthy S.M., Zatarain E., McShane D.J. and Bloch D.A. (1988).** "Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology: new insights into the relative merit of individual criteria". *J. Rheumatol.* 15 (10): 1493–8.
- El Hachmi M., Jadoul M., Lefebvre C., Depresseux G, Houssiau F.A. (2003):** Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. *Lupus* 12: 692–696.
- Esdaile J.M., Joseph L. and Abrahamowicz (1996):** Routine immunologic tests in systemic lupus erythematosus : Is there a need for more studies ? *J. Rheumatol.*, 23 : 1891.
- Fauci A., Braunwald E. and Isselbacherck (2000):** Harrison's principles of internal medicine: 1922 – 1928.
- Fiehn C., Hajjar Y., Mueller K., Waldherr R., Ho A.D. and Andrassy K. (2003):** Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. *Ann Rheum Dis* 62: 435–439.
- Flanc R.S., Roberts M.A., Strippoli G.F., Chadban S.J., Kerr P.G and Atkins R.C. (2004):** Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. *Am J Kidney Dis* 43: 197–208.
- Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T. and Levy R. (1997):** IDEC-C2B8 (Rituximab) anti-CD20

- monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 90: 2188–2195.
- Fraenkel L., Bogardus S. and Concato J. (2002):** Patient preferences for treatment of lupus nephritis. *Arthritis Rheum* 47: 421–428.
- Frédéric A. Houssiau. (2004):** Management of Lupus Nephritis: An Update *J Am Soc Nephrol* 15: 2694-2704.
- Freedman B.I., Spray B.J., Heise E.R., Espeland M.A. and Canzanello V.J. (1993):** A race-controlled human leukocyte antigen frequency analysis in lupus nephritis. *Amer J Kidney Dis* 21:378-382.
- Fujinaka H., Yamamoto T. and Takeya M. (1997):** Suppression of antglomerular basement membrane nephritis by administration of antimonocyte chemoattractant protein 1 antibody in WKY rats. *J. Am. Soc. Nephrol.*, 8 : 1174 – 1178.
- Furie R.A., Cash J.M., Cronin M.E., Katz R.S., Weisman M.H., Aranow C., Liebling M.R., Hudson N.P., Berner C.M., Coutts S. and de Haan H.A. (2001):** Treatment of systemic lupus erythematosus with LJP 394. *J Rheumatol* 28: 257–265. □
- Gallelli B., Moroni G, Sinico R.A., Rimoldi L., Radice A. and Bianchi L. (2009):** Anti-C1q autoantibodies in lupus nephritis. *Ann N Y Acad Sci.*;1173:47-51.
- Garton M.J. and Isenberg (1997):** Clinical features of lupus myositis versus idiopathic myositis : A review of 30 cases. *Br J. Rheumatol.*, 36 : 1067.
- Geoffrey R. Bihl<sup>1</sup>, Michelle Petri<sup>2</sup> and Derek M. Fine (2006):** Kidney biopsy in lupus nephritis look before you leap. *Nephrology Dialysis Transplantation* 21(7):1749-1752.
- Gerard C. and Rollins B.J. (2001):** Chemokines and disease. *Nature Immunol.*, 2 : 108 – 115.
- Gerritsma J.S., Vankooten C. and Gerritsen A.F. (1998):** Transforming growth factor – beta 1 regulates chemokine and complement

production by human proximal tubular epithelial cells. *Kidney Int.*, 53 : 609 – 616.

**Gigante A., Amoroso D., et al. (2006):** Systemic lupus erythematosus and renal involvement: which role of cytokines expression?. *Eur Rev Med Pharmacol Sci.*; 10 (5):223-8.

**Gladman D.D. (1997):** systemic lupus erythematosus : clinical features. In : Klippel JH, Weyand CM, Wortmann RL (eds). *Primer on the Rheumatic diseases*, 11<sup>th</sup> ed., Atlanta : Arthritis foundation, p 267 – 272.

**Gladman D.D. and Urowitz M.B. (1998):** Systemic Lupus Erythematosus: Clinical Features. In: Klippel JH, Dieppe PA, eds. *Rheumatology*. 2<sup>nd</sup> ed. St. Louis, Mo: Mosby; 7.1.1-7.1.18.

**Goldman I., Bennett C., and Drazen J. (2000):** Lupus nephritis. *Cecil textbook of medicine*, 1509 – 1517.

**Goral S., Ynares C., Shappell S.B., Snyder S., Feurer I.D., Kazancioglu R., Fogo A.B. and Helderman J.H (2003):** Recurrent lupus nephritis in renal transplant recipients revisited: It is not rare. *Transplantation* 75: 651–656.

**Grandaliano G, Gesualdo L., Raniari E., Montinaro V., Marro F. and Schena F.P. (1996):** Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides : A pathogenic role in interstitial monocyte recruitment. *J. Am. Soc. Nephrol.*, 7 : 906 – 913.

**Grimaldi C.M., Michael D.J. and Diamond B. (2001):** Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. *J. Immunol.* 167: 1886-1890

**Grohmann J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., Russell A., Dougados M., Emery P., Nuamah I.F., Williams G.R., Becker J.C., Hagerty D.T., Moreland L.W. (2003):** Treatment of rheumatoid arthritis by selective inhibition

- of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 349: 1907–1915.
- Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., Candeloro P., Belladonna M.L., Bianchi R., Fioretti M.C. and Puccetti P. (2002):** CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nat Immunol* 3: 1097–1101.
- Guyton, Arthur C.; Hall, John E. (2006):** Textbook of Medical Physiology. Philadelphia: Elsevier Saunders. pp. 316–317
- Hahn B.H. (1998):** Antibodies to DNA. *N. Engl. J. Med.*, 338 ; 1359 – 1368.
- Hahn B.H., Karpouza G.A. and Tsao B.P. (2005):** Pathogenesis of systemic lupus erythematosus. In: Harris ED, et al. Eds. Kelley's Textbook of Rheumatology, 7th edition. Saunders ;1174-1200.
- Hochberg, M. C.(1997):** Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.*, 40:1725.
- Hodkinson B., Musenge E. And Tikly M. (February 2009):** "Osteoarticular tuberculosis in patients with systemic lupus erythematosus". *QJM* 102: 321.
- Honczarenko K., Budzianowska A. And Ostanek L. (2008):** "Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome". *Neurol. Neurochir. Pol.* 42 (6): 513–517.
- Houssiau F.A. and Ginzler E.M. (2008):** Current treatment of lupus nephritis. *Lupus.* 17 (5) : 426 - 30.
- Houssiau F.A., N'Zeuseu Toukap A., Depresseux G., Maldague B.E., Malghem J., Devogelaer J.P. and Vande Berg B.C. (1998):** Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: Lack of correlation with antiphospholipid antibodies. *Br J Rheumatol* 37: 448–453.
- Hu W., Liu Z., Shen S., Li S., Yao X., Chen H. and Li L. (2003):**

- Cyclosporine A in treatment of membranous lupus nephropathy. *Chin Med J (Engl)* 116: 1827–1830.
- Illei G.G., Tackey E., Lapteva L. and Lipsky P.E. (2004):** Biomarkers in systemic lupus erythematosus. II. Markers of disease activity [review]. *Arthritis Rheum*;50:2048–65.
- JAN J W, VIVETTE D, MELVIN M, SURYA V, CHARLES E, GERALD B L, JAMES E, JAN A, TERENCE C, FRANCO F, AGNES B O, ELLEN M,etal(2004):** The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney International* 65, 521–530
- James, William; Berger, Timothy; Elston, Dirk (2005):** Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders.
- Jardinet D., Lefebvre C., Depresseux G., Lambert M., Devogelaer J.P. and Houssiau F.A. (2000):** Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine. *Rheumatology* 39: 389–392.
- Jason W. Bauer, Michelle Petri, Franak M. Batliwalla, Thearith Koeuth, Joseph Wilson, Catherine Slattery, Angela Panoskaltsis-Mortari, Peter K. Gregersen, Timothy W. Behrens, and Emily C. Baechler (2009):** Interferon-Regulated Chemokines as Biomarkers of Systemic Lupus Erythematosus Disease Activity *ARTHRITIS & RHEUMATISM* ;Vol. 60, No. 10, pp 3098–3107.
- Jayne, D. (2007).:** Current management of lupus nephritis: popular misconceptions. *Lupus.*;16(3):217-20.
- Jayne D., Passweg J., Marmont A., Farge D., Zhao X., Arnold R., Hiepe F., Lisukov I., Musso M., Ou-Yang J., Marsh J., Wulffraat N., Besalduch J., Bingham S.J., Emery P., Brune M., Fassas A., Faulkner L., Ferster A., Fiehn C., Fouillard L., Geromin A., Greinix H., Rabusin M., Saccardi R., Schneider P., Zintl F., Gratwohl A. and Tyndall A. (2004):** European Group for Blood and

Marrow Transplantation; European League Against Rheumatism Registry : Autologous stem cell transplantation for systemic lupus erythematosus. *Lupus* 13: 168–176.

**Jennekens F.G and Kater L. (2002):** The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. *Rheumatology (Oxford)*. 41(6):605-18.

**Jennette J.C. (1998):** Crescentic glomerulonephritis. In : Heptin stalls, pathology of the kidney, 5<sup>th</sup> ed., edited by : Jennette JC, Olsen JL, Schwartz MM, Silva FG, Philadelphia and Lippincott – Raven. P. 625 – 656.

**Jim C. Oates, Sanju Varghese, Alison M. Bland, Timothy P. Taylor, Sally E. Self, Romesh Stanislaus, Jonas S. Almeida, and John M. Arthur.(2009):** Prediction of urinary protein markers in lupus nephritis. *Kidney Int.* 2005 December; 68(6): 2588–2592.

**Jorfen M., Callejas J.L. and Formiga F. (1998):** Fulminant thrombotic thrombocytopenic purpura in systemic lupus erythematosus. *Scand J. Rheumatol.*, 27 : 76.

**Jump R.L., Robinson M.E., Armstrong A.E., Barnes E.V., Kilbourn K.M., Richards H.B. (September 2005).** “Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support”. *J. Rheumatol.* 32 (9): 1699–705.

**Kaisho T., Takeda K., Tsujimura T. et al. (2001):** L Kappa B kinase alpha is essential for mature B cell development and function. *J Exp Med.* 193: 417-426.

**Kakizaki Y., Waga S. and Sugimoto K. (1995):** Production of monocyte chemoattractant protein -1 by bovine glomerular endothelial cells. *Kidney Int.*, 48 : 1866 – 1874.

**Kanta H. and Mohan C. (March 2009):** "Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation". *Genes Immun.*:10.1038/gene.2009.6.

- Keeling D.M. and Isenberg D.A. (1995):** Haematological manifestations of systemic lupus erythematosus (review). *Blood Rev.*, 7 : 199.
- Kelner G.S., Kennedy J., Bacon K.B., Kleyensteuber S. and Jenkins N.A. (1997):** Lymphotactin : A cytokine that represent a new class of chemokine. *Science*, 266 : 1395 – 1399.
- Khamashta M.A. (2006):** Systemic lupus erythematosus and pregnancy. *Best Pract Res Clin Rheumatol.* 20(4):685-94.
- Kiani A.N., Johnson K., Chen C., et al. (2007):** “Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis,” *Journal of Rheumatology*, vol. 36, no. 10, pp. 2224–2230.
- Kim H.L., Lee D.S., Lim C.S., et al. (2002):** The polymorphism of monocyte chemoattractant Protein-1 is associated with the renal disease of SLE. *Am J Kidney Dis* **40**, 1146–52.
- Klippel J.H. (1995):** Predicting who will get lupus nephritis. *J. clin Rheumatol.*, 1 : 257 – 259.
- Kong K., Leung B.P., Law W., Thong B.Y., Chia F., Lian T., Lau T., Chng H., Mohan C. and Howe H. (2007):** Levels of Urine CXCL16,MCP-1 And Serum sTNFR1 Correlate With Renal Disease Activity in SLE.
- Lahita R. (1999):** Systemic lupus erythematosus, 3<sup>rd</sup> ed., San Diego : Academic Press.
- Lauwerys B.R. and Houssiau F.A. (2003):** Involvement of cytokines in the pathogenesis of systemic lupus erythematosus. *Adv Exp Med Biol* 520: 237–251.
- Lauwerys B.R., Garot N., Renauld J.C. and Houssiau F.A. (2000):** Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. *Arthritis Rheum* 43: 1976–1981.
- Lawrence H. Brent (2009):** Nephritis, Lupus: Treatment & Medication .eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease

- Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R. and Isenberg D.A. (2002):** An open study of B lymphocyte depletion in systemic lupus erythematosus. *Arthritis Rheum* 46: 2673–2677.
- Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D. and Lachin J.M. (1992):** A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. *N Engl J Med* 326: 1373–1379.
- Lisignoli G.S., Toneguzzi C., Pozzi A., Piacentini M. and Riccio A. (1999):** Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. *J.Rheumatol.*, 26 : 791– 799.
- Lit L.C., Wong C.K., Tam L.S., Li E.K. and Lam C.W. (2006).** Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. *Ann Rheum Dis* ;65:209.
- Llorente L., Richaud-Patin, Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., Alcocer-Varela J., Grangeot-Keros L., Alarcon-Segovia D., Wijdenes J., Galanaud P. and Emilie D. (2000):** Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. *Arthritis Rheum* 43: 1790–1800.
- Lockshin M.D. and Kirkland M. (2007):** Biology of sex distribution of systemic lupus erythematosus. *Arthritis Rheum.* ; 57 (4) : 608-611.
- Lodi P.J., Garrett D.S. and Kuszewski (1994):** High – resolution solution structure of the beta chemokine MIP-1 beta by multi-dimensional NMR. *Science*, 263 ; 1762 – 1767.
- Looney R.J., Anolik J. and Sanz I. (2002):** B cells as therapeutic targets for rheumatic diseases. *Curr Opin Rheumatol* 16: 180–185.
- Luster A.D. (1998):** Chemokines : Chemotactic cytokines that mediate

inflammation. *N. Engl. J. Med.*, 338 : 436 – 445.

**Manger, Seelen, Marc A., Trouw, L. A. and Daha, M.R. (2003):** Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. *Current Opinion in Nephrology and Hypertension*: November 2003 - Volume 12 - Issue 6 - pp 619-624.

**Mantovani A. (1994):** Biology of disease, tumor associated macrophages in neoplastic progression : A paradigm for the in vivo function of chemokines. *Lab Invest.*, 71 : 5 – 16.

**Marco Tucci, Elena V., Barnes, Eric S., Sobel, Byron P. Croker, Mark S. Segal, Westley H. Reeves, and Hanno B. Richards(2004):** Strong Association of a Functional Polymorphism in the Monocyte Chemoattractant Protein 1 Promoter Gene With Lupus Nephritis. *Arthritis & Rheumatism* Vol. 50, No. 6, pp 1842–1849.

**Marcotucci, A Nicola Calvani, A hanno B. Richards, B Cosima Quatraro, A and Franco Silvestrisa (2005):** The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. *Ann. N.Y. Acad. Sci.* 1051: 421–432 .

**Marks S.D., Williams S.J.<sup>3</sup>, Kjell Tullus<sup>1,2</sup> and Neil J. Sebire (2008):** Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in paediatric lupus nephritis. *Nephrology Dialysis Transplantation* 23 (11) : 3521 - 3526.

**Martens H.A., Nolte I.M., van der Steege G., et al. (March 2009).** "An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus". *Scand. J. Rheumatol.*: 1–7.

**Mary J. Roman, Beth-Ann Shanker, Adrienne Davis, A.B., Michael D. Lockshin, Lisa Sammaritano, Ronit Simantov., Mary K. Crow, Joseph E. Schwartz, Stephen A. Paget, Richard B. Devereux, and Jane E. Salmon. (2003).** "Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus".

- New England Journal of Medicine* **349** (Dec. 18): 2399–2406.
- Maton, Anthea; Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright (1993).** Human Biology and Health. Englewood Cliffs, New Jersey, USA: Prentice Hall.
- McCune W.J., Golbus J., Zeldes W., Bohlke P., Dunne R. and Fox D.A. (1988):** Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. *N Eng J Med* 318:1423-1451.
- Mckay C.R. (1996):** Chemokine receptors and T cell chemotaxis. *J. Exp. Med.*, 184 : 799.
- Mecklenbrauker J., Saijo K & Zheng NY et al. (2002):** Protein kinase C delta controls self-antigen-induced B-cell tolerance. *Nature*; **416**: 860–865.
- Mendoza-Pinto C., García-Carrasco M., Sandoval-Cruz H., et al. (February 2009).** "Risk factors of vertebral fractures in women with systemic lupus erythematosus". *Clin. Rheumatol.* **28**: 579.
- Merrill J.T. and Lahita R.G (1996):** The antiphospholipid syndrome and SLE : Is there a clue in the link between complement and coagulation ? (review). *Lupus*, 5 : 6.
- Mezzano S.A., Barria M. and Drouett M.A. (2001):** Tubular NF – alpha B and AP-1 activation in human proteinuric renal disease. *Kidney Int.*, 60 : 1366 – 1377.
- Mojcik CF, Klippel JH:** End-stage renal disease and systemic lupus erythematosus. *Am J Med* 101:100-107, 1996.
- Mok c.c (2010):** “Update on emerging drug therapies for systemic lupus erythematosus,” *Expert Opinion on Emerging Drugs*, vol. 15, pp. 53–70.
- Mok C.C., Ho C.T., Siu Y.P., Chan K.W., Kwan T.H., Lau C.S., Wong R.W. and Au T.C. (2001):** Treatment of diffuse proliferative

- lupus glomerulonephritis : A comparison of two cyclophosphamide - containing regimens. *Am J Kidney Dis* 38: 256–264.
- Mok C.C., Lau C.S. and Wong R.W. (1998):** Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. *Arthritis Rheum* 41: 831–837.
- Mok C.C., Ying K.Y., Lau C.S., Yim C.W., Ng W.L., Wong W.S. and Au T.C. (2004):** Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial. *Am J Kidney Dis* 43: 269–276.
- Mont M.A., Glueck C.J. and Pacheco I.H. (1997):** Factors for osteonecrosis in systemic lupus erythematosus. *J. Rheumatol.*, 24 : 654.
- Moroni G, Tantardini F. and Ponticelli C. (2003):** Renal replacement therapy in lupus nephritis. *J Nephrol* 16: 787–791.
- Moroni G, Ventura D., Riva P., Panzeri P., Quaglini S., Banfi G, Simonini P., Bader R., Meroni P.L. and Ponticelli C.(2004):** Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. *Am J Kidney Dis* 43: 28–36.
- Moura C.G, Lima I., Barbosa L., Athanzio D., Reis E., Reis M., Burlingame R.W. and Santiago M.W. (2009):** Anti-C1q Antibodies: Association With Nephritis and Disease Activity in Systemic Lupus Erythematosus. *Journal of Clinical Laboratory Analysis* 23 : 19–23
- Murphy P.M., Baggiolini M., Charo I.F. et al. (2000):** International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol. Rev.*; 52: 145–176.
- Myers S.I., Wong L.M. and Charo I.F. (1995):** signal transduction and ligand specificity of the human monocyte chemoattractant protein -1 receptor in transfected embryonic kidney cells. *J Biol*

Chem, 270 : 5786 – 5792.

**Neeraj Dhaun and David C Kluth (2008):** TWEAK: a novel biomarker for lupus nephritis? *Arthritis Research & Therapy* 2009, 11:133.

**Neeraj Dhaun and David C Kluth (2009):** TWEAK: a novel biomarker for lupus nephritis? *Arthritis Research & Therapy*, 11:133 doi:10.1186/ar2846

**Nelson P.J. and Krensky A.M. (1998):** chemokines, lymphocytes and viruses : What goes around, comes around. *Curr Opin Immunol.*, 10 : 265 – 270.

**Noris M., Bernasconi S., Casiraghi F., Sozzani S., Gotti E., Remmuzzi G and Mantovani A. (1995):** MCP-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. *Lab Invest.*, 73 : 804 – 809.

**Neuwelt CM and Young RG (2009).** "Managing neuropsychiatric lupus: Top 10 clinical pearls". *The Journal of Musculoskeletal Medicine* 26 (4).

**Noris M., Sozzani S., Gotti E., et al. (1995):** Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. *Lab Inv* 73, 804–9.

**Nyengaard J.R. and Bendtsen T.F. (2000):** Glomerular number and size in relation to age, kidney weight, and body surface in normal man. *Kidney Int.* 2000 Aug ;58 (2):770-3 .

**Omdal R. (2002):** "Some controversies of neuropsychiatric systemic lupus erythematosus". *Scand. J. Rheumatol.* 31 (4): 192–7.

**Panzer U., Thaiss F. and Zahner G. (2001):** Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocyte recruitment in experimental glomerulonephritis. *Kidney Int.*, 59 : 1762 – 1769.

- Petersen L.J., Brasso K., Pryds M. and Skov P.S. (1996):** Histamine release in intact human skin by MCP-1, RANTES, Macrophage inflammatory protein-1 alpha, stem cell factor, anti – IgE and codeine as determined by an ex vivo skin microdialysis technique. *Allergy Clin Immunol.*, 98 : 790 – 796.
- Petri M. (2000):** Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. *Lupus*, 9 : 170 – 175.
- Petri M. (2007):** The Hopkins Lupus Pregnancy Center: ten key issues in management. *Rheum Dis Clin North Am.* 33(2):227-35, v.
- Petri M., Jones R.J. and Brodsky R.A.(2003):** High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. *Arthritis Rheum* 48: 166–173.
- Pisetsky D.S. (1998):** antibody responses to DNA in normal immunity and aberrant immunity. *Clin Diagn Lab Immunol.*, 5 : 1-6.
- Ponticelli C. (1997):** Treatment of lupus nephritis—The advantages of a flexible approach. *Nephrol Dial Transplant* 12: 2057–2059.
- Premack B.A. and Schall T.J. (1996):** Chemokine receptors: Gateways to inflammation and infection. *Nat Med.*, 2 : 1174 – 1178.
- Proost P., Wuyts A. and Van Damme J (1996):** *Int.J.Clin.Lab.Res.*26:211
- Rahman A. and Isenberg D.A. (2008):** Systemic lupus erythematosus. *N Engl J Med.* Feb 28; 358(9):929-39.
- Reefman P., Kuiper H., Limburg P.C. et al. (2007):** Type I interferons are involved in the development of UVB induced inflammatory skin lesions in Systemic Lupus Erythematosus (SLE) patients. *Ann Rheum Dis.*, 57:411.
- Remuzzi G and Bertani T. (1998):** Pathophysiology of progressive nephropathy. *N. Engl. J. Med.*, 339 : 1448 – 1456.
- Robson M.G., Cook H.T., Botto M., Taylor P.R., Busso N., Salvi R., Pusey C.D., Walport M.J. and Davies K.A. (2001):** Accelerated

- nephrotoxic nephritis is exacerbated in C1q-deficient mice. *J Immunol* 166: 6280–6288.
- Rollins B. (1997):** Chemokines. *Blood*, 90 : 909 – 928.
- Rollins B.J. and Sunday M.E. (1991):** Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. *Mol. Cell. Biol.*, 11 : 3125.
- Romagnani P., Beltrame C., Annunziato F., Lasagni L., Luconi M., Golli G, Cosmi L. and Maggi E. (1999):** Role for interactions between IP -10/MIG and CXCR3 in proliferative glomerulonephritis. *J. Am. Nephrol.*, 10 : 2518 – 2526.
- Rovin B.H. and Phan L.T. (1998):** Chemotactic factors and renal inflammation. *Am. J. Kidney Dis.*, 31 : 1065 – 1084.
- Rovin B.H. and Tan L.C. (1994):** Role of protein kinase pathways in IL-1-induced chemoattractant expression by human mesangial cells. *Kidney Int* 46, 1059–68.
- Rovin B.H., Birmingham D.J., Nagaraja H.N., Yu C.Y. and Hebert L.A. (2007):** “Biomarker discovery in human SLE nephritis,” *Bulletin of the NYU Hospital for Joint Diseases*, vol. 65, no. 3, pp. 187–193.
- Rovin B.H., Dickerson J.A., Jan L.C. and Hebert C.A. (1995):** Activation of NF-kappa B correlations with MCP-1 expression by human mesangial cells. *Kidney Int.*, 48 : 1263 – 1271.
- Rovin B.H., Doe N. and Tan L.C. (1996):** MCP-1 levels in patients with glomerular diseases. *Am. J. Kidney Dis.*, 27 : 640 – 646.
- Rovin B, Song H, Lee A, et al. (2004):** Urine chemokines as biomarkers of systemic lupus erythematosus activity. *Clin Nephrol* 16 (2), 467.
- Rovin B.H., Song H., Birmingham D.J., Hebert L.A., Yu C.Y. and Nagaraja H.N.(2005):** Urine chemokines as biomarkers of human systemic lupus erythematosus activity. *J Am Soc Nephrol*;16:467e73.

- Rovin Brad H., Nathaniel Doe, Laura C. Tan (1996): Monocyte chemoattractant protein-1 levels in patients with glomerular disease. *American Journal of Kidney Diseases (AJKDD)* Volume 27, Issue 5, Pages 640-646 .
- Salmon J.E. and Kimberly R.P. (2000):** Systemic Lupus Erythematosus. In *Manual of Rheumatology and Outpatient Orthopedic disorders. Diagnosis and Therapy*, 4<sup>th</sup> ed., edited by : Paget SA, Gibofsky A and Beary JF, Chapter 30 : 236 – 251.
- Salmon J.E., Millard S.S., Schachter L.A., Arnett F.C., Ginzler E.M., Gourly M.F., Ramsey – Goldman R. and Kimberly R.P. (1996):** FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. *J. Clin Invest.*, 97 : 1348 – 1354.
- Satriano J.A., Hora K. and Shan Z. (1993):** Regulation of monocyte chemoattractant protein 1 and macrophage colony stimulating factor by IFN gamma, tumor necrosis factor alpha, IgG aggregates and cAMP in mouse mesangial cells. *J. Immunol.*, 150 : 1971 – 1978.
- Scheter A.D., Rollins B.J., Zhang Y.J., Charo I.F., Fallon J.T., Giesen P.L. and Taubman M.B. (1997):** Tissue factor is induced by monocyte chemoattractant protein -1 in human aortic smooth muscle and THP-1 cells. *J. Biol. Chem.*, 272 ; 28568 – 28573.
- Schlondorff D., Nelson P.J., Luckow B. and Banas B. (1997):** Chemokines and renal disease. *Kidney Int.*, 51 : 610 – 621.
- Schwarz M., Radeke H.H., Resch K. and Uciechowski P. (1997):** Lymphocyte – derived cytokines induce sequential expression of monocyte and T – c ell specific chemokines in human mesangial cells. *Kidney Int.*, 52 : 1521 – 1531.
- Schwartz, N.; Michaelson, J.S. and Putterman, C. (2007) :** Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. *Ann N Y Acad Sci.* Aug;1109:265-74.
- Segerer S., Mack M., Regele H., Kerjaschki D. and Schlondorff D. (1999):** Expression of the C-C chemokine receptor 5 in human

kidney diseases. *Kidney Int.*, 56 : 52 – 64.

**Segerer S., Nelson P.J. and Schlondroff D. (2000):** Chemokines, chemokine receptors and renal disease : from basic science to pathophysiologic and therapeutic studies. *J. Am. Soc. Nephrol.*, 11 : 152 – 176.

**Seshan SV, Charles J (2009):** Renal Disease in Systemic Lupus Erythematosus With Emphasis on Classification of Lupus Glomerulonephritis: Advances and Implications. *Archives of Pathology & Laboratory Medicine: February 2009, Vol. 133, No. 2, pp. 233-248.*

**Shosaku Narumi, Tsutomu Takeuchi, Yuko Kobayashi, Konosuke Konishi (2000):** Serum levels of ifn-inducible protein-10 relating to the activity of systemic lupus erythematosus doi:10.1006/cyto.2000.0757, available online at <http://www.idealibrary.com> on.

**Singer JM and Plotz CM,(1956):** The latex fixation test. II. Results in rheumatoid arthritis *Am J Med.* 1956 Dec;21(6):893-6.

**Sontheimer R.D. (1998):** Systemic lupus erythematosus and the skin. Lahita R. (ed). 3<sup>rd</sup> ed., San Diego : Academic press, PP. 631– 656.

**Springer T.A. (1994):** Traffic signals for lymphocyte recirculation and leukocyte migration : the multistep paradigm cell, 76:301 – 314.

**Steinberg A.D. and Steinberg S.C. (1991):** Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. *Arthritis Rheum* 34: 945–950.

**Stephen Segerer, Yan Cui, Kelley L-Hudkins, Tracy Goodpaster and Frank Eitner (2000):** Expression of MCP-1 and its receptor CCR2 in human Crescentic glomerulonephritis. *J. Am Soc., Nephrol.*, 11 ; 2231 – 2242.

**Stephen D. Marks, Sue J. Williams, Kjell Tullus and Neil J. Sebire**

- (2008): Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in paediatric lupus nephritis. *Nephrol Dial Transplant* ., 23: 3521–3526.
- Symmons D.P. (1995):** Frequency of lupus in people of African origin. *Lupus*. Jun; 4 (3) : 176 - 8
- Syuto T., Shimizu A., Takeuchi Y., et al. (February 2009).** "Association of antiphosphatidylserine / prothrombin antibodies with neuropsychiatric systemic lupus erythematosus". *Clin. Rheumatol.*
- Takahashi M., Masuyama J., Ikeda U., Kitagawa s., Kasahara T. and Shimada S. (1995):** Suppressive role of endogenous endothelial MCP-1 on monocyte transendothelial migration in vitro. *Arterio Sclero Thromb Vasc Biol.* ,15 : 629 – 636.
- Tan E.M., Cohen A.S. and Fries J.F. (1982):** The 1982 revised criteria for he classification of systemic lupus erythematosus. *Arthritis Rheum.*, 25 : 1271 – 1277.
- Tan E.M., Feltkamp T.E. and Smolen J.S. (1997):** Range of antinuclear antibodies in healthy individuals. *Arthritis Rheum*, 40 : 1601.
- Taul M.W., zandi – Nejad K. and Weening B. (2000):** Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. *Kidney Int.*, 58 : 1664 – 1676.
- Terkeltaub R., Banka C.L., Solan J., Santoro D., Brand K. and Curtiss L.K. (1994):** Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T – lymphocyte chemotactic activity. *Arterio sclera Thromb*, 14 : 47 – 53.
- Thelen M. (2001):** Dancing to the tune of chemokines. *Nature Immunol.*, 2 : 129 – 134.
- Tokoyama H., Wada T., Funichi K., Segawa C., Shimizu M., Kobayashi K., su S., Mukaida N. and Matsushima K. (1998):** Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. *J. Leukocyte Biol.*, 63 : 493 – 499.

- Traynor A.E., Barra W.G., Rosa R.M., Rodriguez J., Oyama Y., Baker S., Brush M. and Burt R.K. (2002):** Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. *Arthritis Rheum* 46: 2917–2923.
- Tucc Mi, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, and Richards HB(2004):** Strong Association of a Functional Polymorphism in the Monocyte Chemoattractant Protein 1 Promoter Gene With Lupus Nephritis. *ARTHRITIS & RHEUMATISM* Vol. 50, No. 6, pp 1842–1849.
- Tucci M, Calvani N, Richards HB, Quatraro C, and Silvestris F (2005 ) :** The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. *Ann. N.Y. Acad. Sci.* 1051: 421–432 .
- Uguccioni D. (1995):** Chemokines, a family of chemotactic cytokines. *Crit Rev Oral Biol. Med.*, 6 : 81 – 176.
- Urowitz M.B. and Gladman D.D. (2000):** Accelerated atheroma in lupus – background. *Lupus*, 9 : 161 – 165.
- van Bruggen MC, Kramers C, Walgreen B, Elema JD, Kallenberg CG, van der Born J, Smeenk RJ, Assmann KJ, Muller S, Monestier M, Berden JH (1997):** Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. *Nephrol Dial Transplant* 12: 57–66.
- Viedt C., Dechend R. and Fei J. (2002a):** Monocyte chemoattractant protein -1 induces inflammatory activation of human tubular epithelial cells : involvement of the transcription factors, nuclear factor – alpha B and activating protein -1. *J. Am Soc. Nephrol.*, 13 : 1534 – 1547.
- Viedt C., Vogel J. and Athanasiou (2002b):** Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear

factor-alpha B and activator protein-1. *Arterioscler thromb Vasc Biol.*, 22 : 914 – 920.

**Villarreal G.M., Drenkard C. and Villa A.R. (1997):** Prevalence of 13 autoantibodies and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. *Lupus*, 6 : 425.

**Wada T., Furuichi K., Segawa – Takaeda C., Shimizu M., Sakai N., Takeda S.I., Takassawa K., Kida H., Kobayashi K.I., Mukaida N. and Ohmoto Y. (2001):** MCP -1 alpha and MCP-1 beta contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. *Kidney Int.*, 56 : 995 – 1003.

**Wada T., Kengo F., Ken K., et al. (1996):** Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. *Kidney Int* **49**, 761–7.

**Wagrowska-Danilewicz M., Stasikowska O. and Danilewicz M. (2005):** Correlative insights into immunoexpression of monocyte chemoattractant protein-1, transforming growth factor beta-1 and CD68+ cells in lupus nephritis. *Pol J Pathol.* ;56(3):115-20.

**Waldman, M. and Appel, G.B.(2006) :** Update on the treatment of lupus nephritis. *Kidney Int* ; 70:1403.

**Wallace D., Goldfinger D., Pepkowitz S. (1997):** A prospective, controlled trial of pulse synchronization cyclophosphamide (CTX)/apheresis for proliferative lupus nephritis. *Arth Rheum* 40(9):S58.

**Wallace D.J. and Hahn B.H. (2007):** Editors. 7th ed. Dubois' lupus erythematosus Baltimore: Williams & Wilkins.

**Wang B., Gladman D.d. and Urowitz M.B. (1998):** Fatigue in lupus is not correlated with disease activity. *J. Rheumatol.*, 25 : 892.

**Wang J., Kay A.B., Fletcher J., Formica M.K. & McAlindon T.E. (2008):** "Is lipstick associated with the development of systemic lupus erythematosus (SLE)?" *Clinical Rheumatology* **29**

(9):1183–1197.

- Wang Y., Rangan G.K., Tay Y.C., Wang y. and Harris D.C.H. (1999):** Induction of monocyte chemoattractant protein -1 by albumin is mediated by nuclear factor alpha B in proximal tubular cells. *J. Am. Soc Nephrol.*, 10 : 1204 – 1213.
- Ward M.M. (2000):** Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. *Kidney Int* 57: 2136–2143.
- Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., Tung K.S. and, Fu S.M. (2004):** Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. *J Exp Med* 199: 255–264.
- Weening J.J., D'Agati V.D., Schwartz M.M., et al. (2004):** The classification of glomerulonephritis in systemic lupus erythematosus revisited. *J Am Soc Nephrol* ; 15:241.
- Wernick R.M., Smith D.L., Houghton D.C., Phillips D.S., Booth J.L., Runckel D.N., Johnson D.S., Brown K.K. and Gaboury C.L. (1993):** Reliability of histologic scoring for lupus nephritis: a community-based evaluation. *Ann Intern Med* 119:805-811.
- Westergren A. (1921):** Studies of suspension stability of the blood in pulmonary tuberculosis. *Am. Rev. Tuberc.*; 14: 94.
- Wiggins R.C., Holzman L.B. and Legault D.J. (1997):** Glomerular inflammation and crescent formation. In : *Immunologic renal diseases*, edited by : Neilson EG, Couser WG, Philadelphia and lippincott – Raven, P. 669 – 682.
- William C. Shiel Jr., (2010):** Systemic Lupus Erythematosus. *Medicine Net.com.home >arthritis center>systemic lupus index.*
- Witter F.R. (2007):** Management of the high-risk lupus pregnant patient. *Rheum Dis Clin North Am.*33(2):253-65, v-vi.

- Xue Z., Wang X., Liu F., et al. (2009):** "Intracranial hypertension syndrome in systemic lupus erythematosus: Clinical analysis and review of the literature". *J. Huazhong Univ. Sci. Technol. Med. Sci.* **29** (1): 107–11.
- Yamauchi F., Kashem A., Endoh M., Nomato Y. and Sakai H. (1996):** Detection of MCP-1 and its receptor in mesangial proliferative glomerulo – nephritis. *Nephrology*, 2 : 93 – 99.
- Ye D.Q., Yang S.G., Li X.P., Hu Y.S., Yin J., Zhang G.Q., et al.(2005):** Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. *Arch Dermatol Res*;297:108.
- Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., Bastian H., Kimberly R.P. and Zhou T. (2001):** A role for B lymphocyte stimulator in systemic lupus erythematosus. *J Immunol* 166: 6
- Zlotnik A., Morales J. and Hedrick J.A. (1999):** Recent advances in chemokines and chemokine receptors. *Crit Rev. Immunol.*, 19 : 1 – 47.
- Zoja C., Liu X.H., Donadelli R., Abbate M., Testa D. and Corna D. (1997):** Renal expression of monocyte chemoattractant protein - 1 in lupus autoimmune mice. *J. Am Soc. Nephrol.*, 8: 720 – 729.